An Open-Label Extension of Two Phase 3 Studies Evaluating Long-Term Efficacy of FMX101 4% Minocycline Foam for the Treatment of Acne Vulgaris. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 3, p. S1, 2019. DOI: 10.25251/skin.3.supp.1. Disponível em: https://skin.dermsquared.com/skin/article/view/728. Acesso em: 4 apr. 2025.